A share price of eFFECTOR Therapeutics Inc [EFTR] is currently trading at $14.39, up 6.99%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EFTR shares have gain 11.12% over the last week, with a monthly amount glided 5.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 25, March 2024, eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024.
From an analyst’s perspective:
eFFECTOR Therapeutics Inc [NASDAQ: EFTR] stock has seen the most recent analyst activity on January 25, 2022, when Stifel downgraded its rating to a Hold and also revised its price target to $6.20 from $20. Previously, Stifel upgraded its rating to Buy on November 09, 2021, and kept the price target unchanged to $20. On October 12, 2021, Credit Suisse initiated with a Outperform rating and assigned a price target of $20 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $20 on October 04, 2021. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $33 as its price target on September 21, 2021. Stifel started tracking with a Hold rating for this stock on September 20, 2021, and assigned it a price target of $20. In a note dated September 13, 2021, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $50 on this stock.
eFFECTOR Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $8.44 and $37.00. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. eFFECTOR Therapeutics Inc [NASDAQ: EFTR] shares were valued at $14.39 at the most recent close of the market. An investor can expect a potential drop of -93.05% based on the average EFTR price forecast.
Analyzing the EFTR fundamentals
Trailing Twelve Months sales for eFFECTOR Therapeutics Inc [NASDAQ:EFTR] were 0.00M which represents -100.00% decline. To continue investigating profitability, this company’s Return on Assets is posted at -1.74, Equity is 11.94 and Total Capital is 6.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -3.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.52 points at the first support level, and at 12.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.99, and for the 2nd resistance point, it is at 15.59.
eFFECTOR Therapeutics Inc [EFTR] reported earnings per share of -$3.42 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.65/share, meaning a difference of -$1.77 and a surprise factor of -107.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$3.25 per share as compared to estimates of -$3.08 per share, a difference of -$0.17 representing a surprise of -5.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for eFFECTOR Therapeutics Inc [NASDAQ:EFTR] is 0.77. In addition, the Quick Ratio stands at 0.77 and the Cash Ratio stands at 0.58.
Transactions by insiders
Recent insider trading involved SR ONE CAPITAL MANAGEMENT, LLC, 10% Owner, that happened on Nov 27 ’23 when 0.61 million shares were sold.
